USA - engelsk - NLM (National Library of Medicine)

janssen biotech, inc. - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml - abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications - in patients undergoing percutaneous coronary intervention - in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours safety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been established. abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in clinical studies. because abciximab may increase the risk of bleeding, abciximab is contraindicated in the following clinical situations: - active internal bleeding - recent (within six weeks) gastrointestinal (gi) or genitourinary (gu) bleeding of clinical significance - history of cerebrovascular accident (cva) within two years, or cva with a significant residual neurological deficit - bleeding diathesis - administration of oral anticoagulan

Den europeiske union - fransk - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leucémie, lymphocytaire, chronique, b-cell - agents antinéoplasiques - mabcampath est indiqué pour le traitement des patients atteints de leucémie lymphoïde chronique à cellules b (bcll) pour lesquels la chimiothérapie associant la fludarabine n'est pas appropriée.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abcur ab - amitriptylinhydrochlorid - filmovertrukne tabletter - 25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abcur ab - amitriptylin - filmovertrukne tabletter - 50 mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alemtuzumab, quantity: 30 mg - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections; polysorbate 80; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; sodium chloride; potassium chloride - the treatment of patients with b-cell chronic lymphocytic leukaemia (cll) who have relapsed after failure of two prior therapies.,mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (b-cll).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abcur ab - amitriptylinhydrochlorid - filmovertrukne tabletter - 10 mg

USA - engelsk - NLM (National Library of Medicine)

eli lilly and company - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abciximab -

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

janssen biologics b.v. - abciximab - injektions-/infusionsvätska, lösning - 2 mg/ml - abciximab 2 mg aktiv substans - abciximab

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

orifarm ab - abciximab - injektions-/infusionsvätska, lösning - 2 mg/ml - abciximab 2 mg aktiv substans - abciximab